The new Medicare alternative payment model aims to improve dementia care coordination.
Essen Health Care announced that it is participating in the Guiding an Improved Dementia Experience (GUIDE) Model, an initiative created by the Centers for Medicare and Medicaid Services (CMS).1 The alternative payment model is meant to provide support and arrange care for patients living with dementia and their unpaid caregivers and allow more patients to receive care in the comfort of their own homes.
More than 55 million people worldwide suffer from dementia, with nearly 10 million new cases added each year.2 The most common form of dementia is Alzheimer’s disease.
The GUIDE model, launched July 1st of last year, is a voluntary nationwide model test scheduled to run until July 1st, 2032. According to CMS, nearly 400 organizations across the nation are participating in the initiative.3 The model provides access to a support line, as well as training, education, and other support services. Individuals, known as care navigators, help dementia patients and their caregivers coordinate various services through programs in their communities.1
"CMS is excited to partner with Essen Health Care under the GUIDE Model," CMS administrator, Chiquita Brooks-LaSure, said in the release. "GUIDE represents a transformative approach to how Medicare supports people living with dementia. The program not only envisions new care pathways for these individuals but also reduces the strain on caregivers, enabling more Americans to receive the care they need in familiar surroundings rather than institutional settings."
"We have always been committed to providing compassionate and comprehensive care to those who need it most. Our participation in the GUIDE Model is a natural extension of that commitment, as we strive to improve the quality of life for people living with dementia and their caregivers. By focusing on coordinated care and offering critical support services, we can help families navigate the challenges of dementia, allowing their loved ones to remain in the comfort of their homes and communities. We are honored to partner with CMS in this important endeavor and look forward to making a meaningful impact on the lives of those we serve," said Dr. Sumir Sahgal, founder and chief medical officer, Essen Health Care.
Women are disproportionately affected by dementia, both as patients and as caregivers. Female patients suffering from dementia spend more years living with the syndrome and have higher mortality rates. As caregivers, they’re the ones who are mostly likely to be taking care of others living with dementia, covering about 70% of care hours.3
"Essen Health Care's participation in the GUIDE Model will provide invaluable resources to those living with dementia and their caregivers," said Imelda Tavas, chief administrative officer, said in the release. "Through this model, we can offer education, support, and respite services that make a significant difference in the daily lives of caregivers and their loved ones."
This was in alignment with an executive order, signed in April 2023, by the Biden administration that aimed to improve job quality, increase and expand care options, and provide more support for the families and caregivers of people with dementia.4 This kind of standard would not only improve qualityof life, but would delay and potentially prevent the need for patients with dementia to be placed in nursing homes or similar facilities.
Essen Health Care Selected by CMS (Centers for Medicare & Medicaid Services) to Test Medicare Dementia Care Model. Essen Health Care. January 27, 2025. Accessed January 28, 2025. https://www.prnewswire.com/news-releases/essen-health-care-selected-by-cms-centers-for-medicare-amp-medicaid-services-to-test-medicare-dementia-care-model-875877947.html
Biden-Harris Administration Takes Historic Action to Increase Access to Quality Care, and Support to Families and Care Workers. April 22, 2024. Accessed January 28, 2025. https://www.cms.gov/newsroom/press-releases/biden-harris-administration-takes-historic-action-increase-access-quality-care-and-support-families#:~:text=The%20U.S.%20Department%20of%20Health,support%20America's%20families%20and%20workers.
Dementia. World Health Organization. March 15, 2023. Accessed January 28, 2025. https://www.who.int/news-room/fact-sheets/detail/dementia#:~:text=Dementia%20is%20a%20syndrome%20that,usual%20consequences%20of%20biological%20ageing
Executive Order 14095—Increasing Access to High-Quality Care and Supporting Caregivers. The American Presidency Project. April 18, 2023. Accessed January 28, 2025. https://www.presidency.ucsb.edu/documents/executive-order-14095-increasing-access-high-quality-care-and-supporting-caregivers
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.